10 Best Cannatech for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The cannatech sector, blending cannabis industry innovation with technology, presents unique opportunities amid evolving regulatory landscapes and consumer trends. These 10 best cannatech stock picks were selected using ValueSense's proprietary intrinsic value analysis, focusing on Quality rating, intrinsic value compared to market pricing, revenue growth, free cash flow (FCF) margins, ROIC, and 1Y returns. Stocks span established tobacco/beverage giants with cannabis exposure (like MO and STZ) to pure-play cannabis firms (CRON, TLRY) and tech innovators (ISPR), prioritizing undervalued names with strong margins or growth potential. This methodology highlights best value stocks in cannatech for diversified watchlists, emphasizing educational analysis of financial metrics without recommending purchases.
Featured Stock Analysis
Stock #1: Altria Group, Inc. (MO)
| Metric | Value |
|---|---|
| Market Cap | $101.9B |
| Quality Rating | 6.9 |
| Intrinsic Value | $111.5 |
| 1Y Return | 20.3% |
| Revenue | $20.9B |
| Free Cash Flow | $11.5B |
| Revenue Growth | 2.3% |
| FCF margin | 54.8% |
| Gross margin | 69.6% |
| ROIC | 77.3% |
| Total Debt to Equity | (744.8%) |
Investment Thesis
Altria Group, Inc. (MO) stands out in the cannatech space with a robust Market Cap of $101.9B and a high Quality rating of 6.9. Its intrinsic value of $111.5 suggests significant undervaluation, supported by impressive profitability metrics including Revenue of $20.9B, Free Cash Flow of $11.5B, FCF margin of 54.8%, Gross margin of 69.6%, and an exceptional ROIC of 77.3%. Despite modest Revenue growth of 2.3% and a high Total Debt to Equity of 744.8%, MO delivered a solid 1Y Return of 20.3%, positioning it as a stable, cash-generative leader with potential in smokeless and cannabis-adjacent products. This analysis reveals MO's strength in high-margin operations, making it a cornerstone for cannatech watchlists seeking reliable income generation.
Key Catalysts
- Exceptional ROIC at 77.3% drives efficient capital use and shareholder value.
- Massive FCF of $11.5B enables dividends, buybacks, and strategic expansions into alt-tobacco including cannabis tech.
- Strong Gross margin 69.6% and FCF margin 54.8% signal operational excellence amid sector volatility.
- Positive 1Y Return of 20.3% outperforms many peers in uncertain markets.
Risk Factors
- Elevated Total Debt to Equity at 744.8% could strain finances if interest rates rise.
- Low Revenue growth of 2.3% may limit upside in fast-evolving cannatech trends.
- Regulatory pressures on tobacco could indirectly impact cannabis diversification efforts.
Stock #2: Constellation Brands, Inc. (STZ)
| Metric | Value |
|---|---|
| Market Cap | $27.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $61.5 |
| 1Y Return | -14.5% |
| Revenue | $9,382.5M |
| Free Cash Flow | $432.4M |
| Revenue Growth | (7.9%) |
| FCF margin | 4.6% |
| Gross margin | 52.0% |
| ROIC | 19.6% |
| Total Debt to Equity | 133.3% |
Investment Thesis
Constellation Brands, Inc. (STZ), with a Market Cap of $27.1B and Quality rating of 6.1, offers cannatech exposure through beverage innovation. Its intrinsic value of $61.5 indicates undervaluation, backed by Revenue of $9,382.5M, Free Cash Flow of $432.4M, FCF margin of 4.6%, Gross margin of 52.0%, and ROIC of 19.6%. Despite a 1Y Return dip to -14.5% and Revenue growth contraction of 7.9%, Total Debt to Equity at 133.3% is manageable. This positions STZ as a mid-cap growth play with recovery potential in cannabis-infused beverages and premium brands.
Key Catalysts
- Solid ROIC of 19.6% reflects efficient returns on invested capital.
- Healthy Gross margin 52.0% supports profitability in competitive beverages.
- Positive FCF of $432.4M provides flexibility for cannatech investments.
- Brand strength in alcohol could pivot to cannabis synergies.
Risk Factors
- Negative Revenue growth of 7.9% signals short-term headwinds.
- 1Y Return decline of -14.5% amid market pressures.
- Total Debt to Equity at 133.3% heightens leverage risks.
Stock #3: Chart Industries, Inc. (GTLS)
| Metric | Value |
|---|---|
| Market Cap | $9,301.0M |
| Quality Rating | 5.9 |
| Intrinsic Value | $192.2 |
| 1Y Return | -1.9% |
| Revenue | $4,291.2M |
| Free Cash Flow | $397.5M |
| Revenue Growth | (9.0%) |
| FCF margin | 9.3% |
| Gross margin | 33.8% |
| ROIC | 5.7% |
| Total Debt to Equity | 108.3% |
Investment Thesis
Chart Industries, Inc. (GTLS) brings industrial tech to cannatech with a Market Cap of $9,301.0M and Quality rating of 5.9. Intrinsic value at $192.2 points to undervaluation, with Revenue of $4,291.2M, Free Cash Flow of $397.5M, FCF margin 9.3%, Gross margin 33.8%, and ROIC 5.7%. Revenue growth of 9.0% and 1Y Return of -1.9% reflect cyclicality, while Total Debt to Equity of 108.3% is notable. GTLS analysis highlights potential in cryogenic tech for cannabis processing.
Key Catalysts
- Strong FCF margin 9.3% aids cash management.
- Positive Free Cash Flow $397.5M funds growth initiatives.
- Industrial expertise applicable to cannatech infrastructure.
- Intrinsic value upside of $192.2 offers margin of safety.
Risk Factors
- Declining Revenue growth -9.0% indicates demand softness.
- Moderate ROIC 5.7% trails top peers.
- High Total Debt to Equity 108.3% in volatile sectors.
Stock #4: Cronos Group Inc. (CRON)
| Metric | Value |
|---|---|
| Market Cap | $975.4M |
| Quality Rating | 5.7 |
| Intrinsic Value | $2.2 |
| 1Y Return | 30.1% |
| Revenue | $166.5M |
| Free Cash Flow | ($5,673.2K) |
| Revenue Growth | 49.0% |
| FCF margin | (3.4%) |
| Gross margin | 34.5% |
| ROIC | (7.5%) |
| Total Debt to Equity | 0.2% |
Investment Thesis
Cronos Group Inc. (CRON), a pure-play cannatech firm, has a Market Cap of $975.4M and Quality rating of 5.7. Intrinsic value of $2.2 suggests room for appreciation, with Revenue $166.5M growing 49.0%, Gross margin 34.5%, but negative Free Cash Flow $5,673.2K, FCF margin -3.4%, and ROIC -7.5%. 1Y Return of 30.1% and low Total Debt to Equity 0.2% highlight growth momentum in cannabis.
Key Catalysts
- Explosive Revenue growth 49.0% in emerging markets.
- Positive 1Y Return 30.1% shows investor interest.
- Minimal Total Debt to Equity 0.2% reduces financial risk.
- Quality rating 5.7 supports operational improvements.
Risk Factors
- Negative FCF and FCF margin -3.4% strain liquidity.
- Poor ROIC -7.5% indicates capital inefficiency.
- Regulatory hurdles in cannabis sector.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #5: Tilray Brands, Inc. (TLRY)
| Metric | Value |
|---|---|
| Market Cap | $828.6M |
| Quality Rating | 6.1 |
| Intrinsic Value | $22.9 |
| 1Y Return | 560.2% |
| Revenue | $1,003.5M |
| Free Cash Flow | ($49.2M) |
| Revenue Growth | 21.0% |
| FCF margin | (4.9%) |
| Gross margin | 28.2% |
| ROIC | (493.2%) |
| Total Debt to Equity | N/A |
Investment Thesis
Tilray Brands, Inc. (TLRY) boasts a Market Cap of $828.6M and Quality rating of 6.1, with intrinsic value $22.9 signaling undervaluation. Revenue $1,003.5M grew 21.0%, but Free Cash Flow -$49.2M, FCF margin -4.9%, Gross margin 28.2%, and ROIC -493.2% show challenges. Exceptional 1Y Return of 560.2% underscores volatility and potential. Total Debt to Equity N/A.
Key Catalysts
- Massive 1Y Return 560.2% from market momentum.
- Revenue growth 21.0% in core cannabis ops.
- High intrinsic value $22.9 vs. current pricing.
- Brand expansion in global markets.
Risk Factors
- Severely negative ROIC -493.2% erodes value.
- Ongoing FCF losses -$49.2M.
- High sector competition and regulation.
Stock #6: Cannae Holdings, Inc. (CNNE)
| Metric | Value |
|---|---|
| Market Cap | $782.2M |
| Quality Rating | 4.4 |
| Intrinsic Value | $23.8 |
| 1Y Return | -27.2% |
| Revenue | $430.2M |
| Free Cash Flow | ($46.6M) |
| Revenue Growth | (6.9%) |
| FCF margin | (10.8%) |
| Gross margin | 8.3% |
| ROIC | (156.4%) |
| Total Debt to Equity | 17.8% |
Investment Thesis
Cannae Holdings, Inc. (CNNE) features a Market Cap $782.2M and lower Quality rating 4.4, with intrinsic value $23.8. Revenue $430.2M declined 6.9%, Free Cash Flow -$46.6M, FCF margin -10.8%, Gross margin 8.3%, ROIC -156.4%, and 1Y Return -27.2%. Total Debt to Equity 17.8% is moderate; analysis points to turnaround potential in holdings.
Key Catalysts
- Intrinsic value $23.8 offers upside.
- Manageable Total Debt to Equity 17.8%.
- Diversified holdings with cannatech ties.
- Potential for margin recovery.
Risk Factors
- Negative ROIC -156.4% and FCF.
- Declining Revenue growth -6.9%.
- Weak 1Y Return -27.2%.
Stock #7: SNDL Inc. (SNDL)
| Metric | Value |
|---|---|
| Market Cap | $400.2M |
| Quality Rating | 5.2 |
| Intrinsic Value | $4.9 |
| 1Y Return | -14.9% |
| Revenue | CA$951.6M |
| Free Cash Flow | CA$57.6M |
| Revenue Growth | 4.4% |
| FCF margin | 6.1% |
| Gross margin | 27.0% |
| ROIC | (14.7%) |
| Total Debt to Equity | 14.1% |
Investment Thesis
SNDL Inc. (SNDL) has Market Cap $400.2M, Quality rating 5.2, intrinsic value $4.9. Revenue CA$951.6M with 4.4% growth, Free Cash Flow CA$57.6M, FCF margin 6.1%, Gross margin 27.0%, ROIC -14.7%, 1Y Return -14.9%, Total Debt to Equity 14.1%. Positive FCF stands out in cannabis retail/tech.
Key Catalysts
- Positive Free Cash Flow CA$57.6M.
- Steady Revenue growth 4.4%.
- Low Total Debt to Equity 14.1%.
- Retail-cannatech hybrid model.
Risk Factors
- Negative ROIC -14.7%.
- 1Y Return decline -14.9%.
- Currency exposure (CAD).
Stock #8: Canopy Growth Corporation (CGC)
| Metric | Value |
|---|---|
| Market Cap | $300.0M |
| Quality Rating | 4.5 |
| Intrinsic Value | $3.2 |
| 1Y Return | -48.1% |
| Revenue | $305.1M |
| Free Cash Flow | ($95.3M) |
| Revenue Growth | 8.8% |
| FCF margin | (31.2%) |
| Gross margin | 22.4% |
| ROIC | (12.8%) |
| Total Debt to Equity | 31.0% |
Investment Thesis
Canopy Growth Corporation (CGC) shows Market Cap $300.0M, Quality rating 4.5, intrinsic value $3.2. Revenue $305.1M up 8.8%, but Free Cash Flow -$95.3M, FCF margin -31.2%, Gross margin 22.4%, ROIC -12.8%, 1Y Return -48.1%, Total Debt to Equity 31.0%. Growth amid losses typical for scale-ups.
Key Catalysts
- Revenue growth 8.8% in competitive field.
- Established global cannabis brand.
- Intrinsic value provides buffer.
- Potential regulatory tailwinds.
Risk Factors
- Heavy FCF burn -$95.3M.
- Poor 1Y Return -48.1%.
- Negative ROIC -12.8%.
Stock #9: Aurora Cannabis Inc. (ACB)
| Metric | Value |
|---|---|
| Market Cap | $223.6M |
| Quality Rating | 5.8 |
| Intrinsic Value | $6.0 |
| 1Y Return | 6.3% |
| Revenue | CA$379.5M |
| Free Cash Flow | CA$28.4M |
| Revenue Growth | 28.0% |
| FCF margin | 7.5% |
| Gross margin | 42.5% |
| ROIC | (1.1%) |
| Total Debt to Equity | N/A |
Investment Thesis
Aurora Cannabis Inc. (ACB) with Market Cap $223.6M, Quality rating 5.8, intrinsic value $6.0. Revenue CA$379.5M grew 28.0%, Free Cash Flow CA$28.4M, FCF margin 7.5%, Gross margin 42.5%, ROIC -1.1%, 1Y Return 6.3%, Total Debt to Equity N/A. Improving metrics signal recovery.
Key Catalysts
- Robust Revenue growth 28.0%.
- Positive FCF CA$28.4M and margin 7.5%.
- High Gross margin 42.5%.
- Modest 1Y Return 6.3%.
Risk Factors
- Lingering negative ROIC -1.1%.
- Small cap volatility.
- CAD revenue exposure.
Stock #10: Ispire Technology Inc. (ISPR)
| Metric | Value |
|---|---|
| Market Cap | $211.9M |
| Quality Rating | 5.6 |
| Intrinsic Value | $1,306.2 |
| 1Y Return | -21.0% |
| Revenue | $98.4B |
| Free Cash Flow | ($16.8B) |
| Revenue Growth | 149.4% |
| FCF margin | (17.1%) |
| Gross margin | 17.9% |
| ROIC | (49.4%) |
| Total Debt to Equity | (262.0%) |
Investment Thesis
Ispire Technology Inc. (ISPR), Market Cap $211.9M, Quality rating 5.6, intrinsic value $1,306.2 (notable upside). Revenue $98.4B surged 149.4%, Free Cash Flow -$16.8B, FCF margin -17.1%, Gross margin 17.9%, ROIC -49.4%, 1Y Return -21.0%, Total Debt to Equity -262.0%. Hyper-growth in vaping tech for cannabis.
Key Catalysts
- Explosive Revenue growth 149.4%.
- Massive intrinsic value potential $1,306.2.
- Tech innovation in inhalation devices.
- Scale opportunities.
Risk Factors
- Huge FCF losses -$16.8B.
- Negative ROIC -49.4%.
- Debt structure concerns -262.0%.
Portfolio Diversification Insights
These cannatech stock picks offer sector allocation across tobacco (MO), beverages (STZ), industrial tech (GTLS), and pure cannabis (CRON, TLRY, SNDL, CGC, ACB, ISPR) plus holdings (CNNE). Large-caps like MO provide stability with high ROIC/FCF, balancing small-cap growth plays like TLRY (560.2% 1Y return) and ISPR (149.4% revenue growth). Diversify by weighting 40% stable (MO/STZ), 30% mid-growth (GTLS/CRON), 30% high-volatility (TLRY/CGC/ISPR) to mitigate risks like negative FCF in cannabis firms while capturing upside from undervalued intrinsic values. This mix enhances stock watchlist resilience.
Market Timing & Entry Strategies
Consider positions during regulatory clarity (e.g., U.S. rescheduling) or post-earnings beats on revenue growth. For undervalued names (high intrinsic value vs. price like MO, GTLS, ISPR), dollar-cost average on dips below key supports. Monitor FCF trends—enter positives like SNDL/ACB on strength, avoid heavy exposure to chronic losers until ROIC improves. Use ValueSense tools for real-time intrinsic updates; scale in over 3-6 months for volatility.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These 10 best cannatech stock picks were chosen via ValueSense metrics like Quality rating, intrinsic value, revenue growth, and ROIC, focusing on undervalued opportunities across the sector.
What's the best stock from this list?
MO leads with top Quality rating 6.9, ROIC 77.3%, and FCF $11.5B, but TLRY's 560.2% 1Y Return suits aggressive watchlists—compare via intrinsic values.
Should I buy all these stocks or diversify?
Diversify across large-cap stability (MO/STZ) and growth (ISPR/CRON) to balance risks like negative FCF; this collection supports a stock watchlist approach.
What are the biggest risks with these picks?
Key concerns include high debt (MO/STZ), negative FCF/ROIC in cannabis pure-plays (TLRY/CGC), and regulatory volatility affecting the entire cannatech sector.
When is the best time to invest in these stocks?
Time entries on positive catalysts like revenue beats or policy shifts, using intrinsic value gaps for undervalued cannatech stocks like GTLS and ISPR.